Roche Introduces Cobas Hepatitis D Virus Test, First Fully Automated Diagnostic Solution To Identify Most Severe Form Of Viral Hepatitis
ROCHE HOLDINGS AG
ROCHE HOLDINGS AG
ROCHE HOLDINGS AG
ROCHE HOLDINGS AG RHHBY | 0.00 | |
ROCHE HOLDINGS AG RHHBF | 0.00 | |
ROCHE HOLDINGS AG RHHVF | 0.00 |
- The new test enables clinicians to reliably diagnose HDV and monitor patients’ treatment response.
- Hepatitis D affects nearly 12 million of people globally and is considered the most aggressive form of viral hepatitis, often leading to liver failure and cancer faster than other types.
- The cobas HDV test is the first high-throughput, fully automated HDV assay on the market, addressing the urgent need for a consistent, widely accessible solution and expanding access to critical testing just as new treatments for the disease become available.